New 52-week high$20.43+0.3% vs prior high · 2026-10-22
Takeda's ADRs just set a fresh 52-week high at $20.43, the fourth record in a week for the drugmaker.
Companies
Takeda Pharmaceutical
$41.85
▲ $0.94 (+2.29%) today
Markets open · 12:43pm ET
About Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited is a global R&D-driven biopharmaceutical company. It researches, develops, manufactures and commercializes pharmaceutical products and also earns out-licensing and service income. It reports a single operating segment.
Its revenue is organized into six key business areas:
- **Gastroenterology:** ENTYVIO, GATTEX/REVESTIVE, TAKECAB/VOCINTI, EOHILIA.
- **Rare Diseases:** TAKHZYRO, ELAPRASE, ADVATE, LIVTENCITY, VONVENDI, ADZYNMA.
- **Plasma-Derived Therapies:** immunoglobulins such as HYQVIA, CUVITRU and GAMMAGARD LIQUID, plus albumin.
- **Oncology:** ADCETRIS, LEUPLIN/ENANTONE, NINLARO, ICLUSIG, FRUZAQLA, MIMRYLO.
- **Vaccines:** QDENGA, NUVAXOVID.
- **Neuroscience:** VYVANSE/ELVANSE, TRINTELLIX, ORZEYFUL.
R&D focuses on three core therapeutic areas: Gastrointestinal and Inflammation, Neuroscience (orexin biology), and Oncology. Key late-stage assets include zasocitinib, arcotatug tavatecan, elritercept, TAK-928 and fazirsiran.
The United States is the largest market, followed by Europe, Japan, Latin America and China. The company is executing a transformation program and is led by CEO Julie Kim. Updated
Frequently Asked Questions
What does Takeda Pharmaceutical do?
Takeda Pharmaceutical Company Limited is a global R&D-driven biopharmaceutical company. It researches, develops, manufactures and commercializes pharmaceutical products and also earns out-licensing and service income.